Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18758187 | 0.97 | SMN1; SMN2 (0.53) | SMN1; SMN2TSHRHSD17B10CASP1CASP7 | |
| SCHEMBL12284024 | 0.93 | MGLL (0.51) | SMN1; SMN2TSHRHSD17B10RAB9AALDH1A1 | |
| SCHEMBL17486903 | 0.93 | MGLL (0.51) | SMN1; SMN2TSHRHSD17B10RAB9AALDH1A1 | |
| SCHEMBL13401575 | 0.92 | MGLL (0.47) | SMN1; SMN2TSHRHSD17B10CASP1CASP7 | |
| SCHEMBL15143431 | 0.92 | MGLL (0.47) | SMN1; SMN2TSHRHSD17B10CASP1CASP7 | |
| SCHEMBL24136290 | 0.92 | MGLL (0.47) | SMN1; SMN2TSHRHSD17B10CASP1CASP7 | |
| SCHEMBL16329201 | 0.92 | MGLL (0.47) | SMN1; SMN2TSHRHSD17B10CASP1CASP7 | |
| SCHEMBL24591874 | 0.92 | MGLL (0.47) | SMN1; SMN2TSHRHSD17B10CASP1CASP7 | |
| SCHEMBL16546771 | 0.92 | MGLL (0.47) | SMN1; SMN2TSHRHSD17B10CASP1CASP7 | |
| SCHEMBL13311294 | 0.92 | MGLL (0.47) | SMN1; SMN2TSHRHSD17B10CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717577-B2 | Method for preparing long-acting drug conjugate through preparation of intermediate | HANMI PHARM. CO., LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
| US-11717577-B2 | Method for preparing long-acting drug conjugate through preparation of intermediate | HANMI PHARM. CO., LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717577-B2 | Method for preparing long-acting drug conjugate through preparation of intermediate | GNRHR, UGT1A7, UGT1A3 | SMN1; SMN2 541/4885TSHR 406/4885HSD17B10 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.